DOCSLIB.ORG

EDTA Chelation Therapy in the Treatment of Toxic Metals Exposure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EDTA Chelation Therapy in the Treatment of Toxic Metals Exposure Original Article Spatula DD. 2011; 1(2):81-89 EDTA chelation therapy in the treatment of toxic metals exposure Toksik metallere maruz kalım tedavisinde EDTA şelasyon terapisi Nina Mikirova1, Joseph Casciari1, Ronald Hunninghake1, Neil Riordan1,2 1Riordan Clinic, Wichita, Kansas, USA. 2Medistem Inc, San Diego, California, USA SUMMARY BACKGROUND: Metal induced toxicity with wide range of physiological, biochemical and behavioral dysfunctions was reported in many studies. The chelation has been used for treatment to toxic metals’ exposure for many years. In our current clinical study, we compared different chelation protocols and two forms of EDTA (sodium calcium edetate and sodium edetate) in treatments of toxic metal exposure. METHODS: A 24 h urine samples were collected from each subject before and after treatment by Ca-EDTA or Na-EDTA. The levels of toxic and essential metals were measured by Atomic Absorption Spectrometer (AAS) with graphite furnace and by Inductively Coupled Plasma Atomic Emission Spectrometer (ICP-AES). The cellular levels of ATP were determined by ATP-bioluminescence assay. Mitochondrial potential was measured by fluorometer and flow-cytometer after cells’ staining by mitochondrial dye. RESULTS: Data from over 600 patients with a variety of complaints, but not acute toxic mineral exposure, given chelation therapy with sodium EDTA or calcium EDTA, were analyzed. Ca-EDTA and Na-EDTA at intravenous infusions of 3 g per treatment were equally effective in removing lead from the body, while Ca-EDTA was more effective in aluminum removal. The removal of lead was dose dependent but non-linear. Chelation by different doses of Na-EDTA (3 g and 1 g) resulted in mean difference in lead urine less than 50%. In addition, deficiencies in essential minerals correlated with greater pre-treatment lead and aluminum levels. The intrinsic toxicity of EDTA on cells was investigated. EDTA concentrations above 600 uM reduced cellular energy metabolism. CONCLUSION: Based on our data, we proposed that low dosages of chelating agents might be preferential for patients with no– occupational exposure, as the benefit of chelation is not linear with dosage, the risk of exposure to antidotes is increasing with increased dosages, and excretion of essential metals significantly increases with increased antidote dosage. Keywords: NADH, chelation, lead, essential metals ÖZET GİRİŞ: Birçok çalışmada, metal zehirlenmelerine fizyolojik, biyokimyasal ve davranışsal fonksiyon bozukluklarının eşlik ettiği rapor edilmişitir. Toksik metallere maruz kalım tedavisi için yıllardır şelasyon kullanılmaktadır. Şimdiki klinik çalışmamızda, toksik metallere maruz kalımın tedavisinde, farklı şelasyon protokollerini ve iki EDTA formunu (sodyum kalsiyum EDTA ve sodyum EDTA) karşılaştırdık. YÖNTEM: Ca-EDTA veya Na-EDTA ile tedavi öncesinde ve sonrasında, her denekten 24 saatlik idrar örnekleri toplandı. Toksik ve esansiyel metallerin düzeyleri, grafit fırınlı atomik absorbsiyon spektrometresi (AAS) ve indüktif olarak eşleştirilmiş plazma atomik emisyon spektrometresi (ICP-AES) ile ölçüldü. Hücresel ATP düzeyleri, ATP-biyolüminesans analizi ile saptandı. Mitokondriyal potansiyel, hücrelerin mitokondri boyası ile boyanmasından sonra florimetre ve akış sitometresi ile ölçüldü. BULGULAR: Çeşitli şikayetleri olan fakat akut toksik mineral maruz kalımı olmayan, Na-EDTA ve Ca-EDTA ile şelasyon tedavisi alan 600’ün üzerindeki hastadan elde edilen veriler değerlendirildi. Ca-EDTA ve Na-EDTA’nın tedavi başına 3 g intravenöz infüzyonu, kurşunun vücuttan uzaklaştırılmasında eşit derecede etkinken; Ca-EDTA, alüminyumun uzaklaştırılmasında daha etkindi. Kurşunun uzaklaştırılması, doz bağımlıydı; fakat, doğrusal değildi. Farklı Na-EDTA dozları (3g ve 1g) ile şelasyon, idrar kurşununda %50’den daha az ortalama farklılıkla sonuçlandı. Ayrıca, esansiyel minerallerdeki eksiklikler, tedavi öncesi daha fazla kurşun ve alüminyum düzeyleri ile orantılıydı. Hücreler üzerine EDTA’nın intrensek toksisitesi araşıtırıldı. EDTA, 600 µM üzerindeki konsantrasyonlarda hücresel enerji metabolizmasını azalttı. SONUÇ: Verilere göre; şelasyonun faydası dozla orantılı olmadığından, antidotlara maruziyet riski yüksek dozlarda arttığından ve esansiyel metallerin atılımı yüksek antidot dozları ile arttığından dolayı, şelasyon ajanlarının düşük dozları mesleki olmayan maruz kalımlar için öncelikli olabilir. Anahtar Kelimeler: NADH, şelasyon, kurşun, esansiyel metaller Corresponding Author: Received March 01, 2011; accepted May 04, 2011 Nina Mikirova, DOI 10.5455/spatula.20110504045803 Riordan Clinic, Wichita, KS, USA, email: [email protected]. Published online in ScopeMed (www.scopemed.org). Spatula DD. 2011; 1(2): 81-89. Spatula DD 81 EDTA chelation therapy INTRODUCTION conducted in vitro experiments examining effects of each chelating agent on cellular lead toxicity, The build-up of heavy metals in the body can mitochondrial potential, and ATP production. lead to a variety of health problems [1-3]. Poisonous or nonessential metals such as lead (Pb), mercury MATERIALS AND METHODS (Hg), cadmium (Cd), and aluminium (Al) have been associated with pathologies in the nervous, Clinical Studies cardiovascular, haemotopoietic, gastrointestinal and Data from 600 patients treated with chelation immunological systems as well as renal dysfunction, therapy over a ten-year period (1999-2010) were anaemia, liver problems, cancer, and Alzheimer’s analyzed. Each patient exhibited long-term effects of disease [4-15]. In addition, nutritional trace elements toxic metal exposure. Prior to the onset of treatment, can be toxic at concentrations outside their each patient was screened for adequate kidney physiological range. Excessive levels of iron (Fe), functioning by assaying fasting serum creatinine manganese (Mn), copper (Cu), chromium (Cr) and (levels <1.7mg/dL were considered acceptable). zinc have been associated with conditions such as Four different chelation protocols were used over degenerative brain diseases, oxidative damage and this time period, each involving infusions in either heart problems [16-20]. Thus, it is important to sterile water or Ringers solution. 1) Na-EDTA regulate essential minerals while limiting toxic metal Normal: 3g Na-EDTA, 3 hr IV infusion, build-up in the body, and a means of clearing toxic supplements: 15g vitamin C, vitamin B6, or excess metals from the body is needed. magnesium chloride, and heparin. 2) Na-EDTA Chelation therapy has been proposed for Mini: 1g Na-EDTA, 1.5 hr IV infusion, removing poisonous metals such as Pb, Hg, Cd, and supplements: vitamin B6, and magnesium chloride. Al, as well as reducing abnormal accumulations of 3) Ca-EDTA Normal: 3g Ca-EDTA, 1 hr IV trace nutrients such as Fe, Cu, and Zn [21-24]. infusion, supplements: 15 to 25 g vitamin C, vitamin Chelation therapy employs anionic chelating agents B6, and magnesium chloride. 4) Ca-EDTA Mini: such as ethylene diaminetetraacetic acid (EDTA) to 0.10 g Ca-EDTA, 10 min IV infusion, supplements: bind heavy metal cations found in the blood. Once vitamin B6, and magnesium chloride. Regarding the EDTA bound, these metals can be removed through supplements used, vitamin B6 was used to prevent the kidneys. “chelation headaches” while magnesium chloride There is evidence that EDTA chelation benefits was used to prevent cramps associated with patients by removing toxic and trace elements from magnesium deficiency. Vitamin C is thought to diseased organs and blood vessel walls [25-29]. The assist in lead removal, and heparin was to prevent US Food and Drug administration has approved clotting at the infusion site. Patients were given ten intravenous use of sodium EDTA (Na-EDTA) for or more treatments, with mineral levels being assays treatment of hypercalcaemia, but its broader use in before and after each treatment. improving cardiovascular health is still considered Before and after the first treatment, body burden controversial [30-34]. Because Na-EDTA therapy of heavy metals, including lead, was determined by requires very slow (3 hr for a 3g IV dose) infusion, collecting urine over a twenty-four hour period for calcium EDTA (Ca-EDTA) has been employed in its analysis. Aluminium, lead, cadmium and manganese place. Ca-EDTA is FDA approved for treating levels in urine were measured by the use of Perkin- serious cases of lead poisoning. Elmer 4100ZL AAS with graphite furnace by The purpose of our study is to compare the standard protocols. Calcium, magnesium, iron, effects Na-EDTA and Ca-EDTA on toxic and copper and zinc were also analyzed on a Perkin- essential mineral levels in the body. We analyzed Elmer ICP-AES (Model 3300 DV). data collected over a ten-year period in over six- hundred patients given chelation therapy, measuring Statistics levels of Al, Pb, Cd, Mn, Ca, Mg, Fe, Cu, and Zn. Data from the various protocols were compared Over this time period two chelation regiments were statistically as follows. A Kolmogorov-Smirnov test employed for each chelating agent: a “normal” was used to determine if the data were normally regiment employing three grams of the chelating distributed. If not, Wilcoxon test was used for agent along with 15–25 grams of intravenous comparing groups. If analysis supported the normal vitamin C; and a “mini” regiment employing lower distribution of data, data were analyzed using chelating agent doses (1 g for Na-EDTA, 0.05-0.1 g Student’s t-test. P-values of 0.05 or less are for Ca-EDTA) without vitamin C. We also considered statistically significant. 82 Spatula DD
Load more

Recommended publications
  • Effects of Calcium Chelation on Digitalis-Induced Cardiac Arrhythmias by Paul Szekely and N
    Br Heart J: first published as 10.1136/hrt.25.5.589 on 1 September 1963. Downloaded from Brit. Heart J., 1963, 25, 589. EFFECTS OF CALCIUM CHELATION ON DIGITALIS-INDUCED CARDIAC ARRHYTHMIAS BY PAUL SZEKELY AND N. A. WYNNE From the Cardiovascular Department, Newcastle General Hospital, and the Department ofPhysiology, King's College, University of Durham Received November 19, 1962 Several studies have already shown that cardiac arrhythmias caused by digitalis can be abolished by the induction of hypocalcaemia (Page and Real, 1955; Smith and Grinnell, 1955; Gubner and Kallman, 1957; Kabakow and Brothers, 1958; Surawicz et al., 1959; Cohen et al., 1959; Rosenbaum, Mason, and Seven, 1960; Surawicz, 1960; Soffer, Toribara, and Sayman, 1961). The rationale of inducing hypocalcemia as an anti-arrhythmic measure is based on experimental and clinical obser- vations relating to the direct myocardial action of calcium and to the interaction between calcium, potassium, and digitalis. Low calcium concentration decreases myocardial irritability (Brooks et al., 1955) and it also increases the intracellular potassium concentration (Rosenbaum et al., 1960). There is also a synergistic action between calcium and digitalis, which was observed in the presence of digitalis intoxication (Nalbandian et al., 1957). The present study was undertaken copyright. in order to assess the value of induced hypocalcemia in the management of cardiac arrhythmias caused by digitalis. MATERIAL AND METHODS Forty-eight experiments were carried out under general aneesthesia on 46 cats and 2 dogs. Cardiac arrhythmia was induced by the intravenous administration of tincture of digitalis as previously described http://heart.bmj.com/ (Szekely and Wynne, 1951).
    [Show full text]
  • New Brunswick Drug Plans Formulary
    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
    [Show full text]
  • Review of Succimer for Treatment of Lead Poisoning
    Review of Succimer for treatment of lead poisoning Glyn N Volans MD, BSc, FRCP. Department of Clinical Pharmacology, School of Medicine at Guy's, King's College & St Thomas' Hospitals, St Thomas' Hospital, London, UK Lakshman Karalliedde MB BS, DA, FRCA Consultant Medical Toxicologist, CHaPD (London), Health Protection Agency UK, Visiting Senior Lecturer, Division of Public Health Sciences, King's College Medical School, King's College , London Senior Research Collaborator, South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, Peradeniya, Sri Lanka. Heather M Wiseman BSc MSc Medical Toxicology Information Services, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK. Contact details: Heather Wiseman Medical Toxicology Information Services Guy’s & St Thomas’ NHS Foundation Trust Mary Sheridan House Guy’s Hospital Great Maze Pond London SE1 9RT Tel 020 7188 7188 extn 51699 or 020 7188 0600 (admin office) Date 10th March 2010 succimer V 29 Nov 10.doc last saved: 29-Nov-10 11:30 Page 1 of 50 CONTENTS 1 Summary 2. Name of the focal point in WHO submitting or supporting the application 3. Name of the organization(s) consulted and/or supporting the application 4. International Nonproprietary Name (INN, generic name) of the medicine 5. Formulation proposed for inclusion 6. International availability 7. Whether listing is requested as an individual medicine or as an example of a therapeutic group 8. Public health relevance 8.1 Epidemiological information on burden of disease due to lead poisoning 8.2 Assessment of current use 8.2.1 Treatment of children with lead poisoning 8.2.2 Other indications 9.
    [Show full text]
  • Chelation Therapy
    Medical Policy Chelation Therapy Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History Policy Number: 122 BCBSA Reference Number: 8.01.02 NCD/LCD: N/A Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Chelation therapy in the treatment of the following conditions is MEDICALLY NECESSARY: • Extreme conditions of metal toxicity • Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to nontransfusion-dependent thalassemia (NTDT) • Wilson's disease (hepatolenticular degeneration), or • Lead poisoning. Chelation therapy in the treatment of the following conditions is MEDICALLY NECESSARY if other modalities have failed: • Control of ventricular arrhythmias or heart block associated with digitalis toxicity • Emergency treatment of hypercalcemia. NaEDTA as chelation therapy is considered NOT MEDICALLY NECESSARY. Off-label applications of chelation therapy are considered INVESTIGATIONAL, including, but not limited to: • Alzheimer’s disease • Arthritis (includes rheumatoid arthritis) • Atherosclerosis, (e.g., coronary artery disease, secondary prevention in patients with myocardial infarction, or peripheral vascular disease) • Autism • Diabetes • Multiple sclerosis. 1 Prior Authorization Information Inpatient • For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient. Outpatient • For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient. Outpatient Commercial Managed Care (HMO and POS) Prior authorization is not required. Commercial PPO and Indemnity Prior authorization is not required. Medicare HMO BlueSM Prior authorization is not required.
    [Show full text]
  • Sodium Cellulose Phosphate Sodium Edetate
    Sevelamer/Sodium Edetate 1463 excreted by the kidneys. It may be used as a diagnostic is not less than 9.5% and not more than 13.0%, all calculated on supplement should not be given simultaneously with test for lead poisoning but measurement of blood-lead the dried basis. The calcium binding capacity, calculated on the sodium cellulose phosphate. dried basis, is not less than 1.8 mmol per g. concentrations is generally preferred. Sodium cellulose phosphate has also been used for the Sodium calcium edetate is also a chelator of other Adverse Effects and Precautions investigation of calcium absorption. heavy-metal polyvalent ions, including chromium. A Diarrhoea and other gastrointestinal disturbances have Preparations cream containing sodium calcium edetate 10% has been reported. USP 31: Cellulose Sodium Phosphate for Oral Suspension. been used in the treatment of chrome ulcers and skin Sodium cellulose phosphate should not be given to pa- Proprietary Preparations (details are given in Part 3) sensitivity reactions due to contact with heavy metals. tients with primary or secondary hyperparathyroidism, Spain: Anacalcit; USA: Calcibind. Sodium calcium edetate is also used as a pharmaceuti- hypomagnesaemia, hypocalcaemia, bone disease, or cal excipient and as a food additive. enteric hyperoxaluria. It should be used cautiously in pregnant women and children, since they have high Sodium Edetate In the treatment of lead poisoning, sodium calcium calcium requirements. Sodu edetynian. edetate may be given by intramuscular injection or by Patients should be monitored for electrolyte distur- intravenous infusion. The intramuscular route may be Эдетат Натрия bances. Uptake of sodium and phosphate may increase CAS — 17421-79-3 (monosodium edetate).
    [Show full text]
  • Uses and Administration Adverse Effects and Precautions Pharmacokinetics Uses and Administration
    1549 The adverse effects of dicobalt edetate are more severe in year-old child: case report and review of literature. Z Kardiol 2005; 94: References. 817-2 3. the absence of cyanide. Therefore, dicobalt edetate should I. Schaumann W, et a!. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur 1 not be given unless cyanide poisoning is confirmed and 30: Administration in renal impairment. In renal impairment, Clin Pharmacol 1986; 527-33. poisoning is severe such as when consciousness is impaired. 2. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab elimination of antibody-bound digoxin or digitoxin is therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; Oedema. A patient with cyanide toxicity developed delayed1·3 and antibody fragments can be detected in the 28: 483-93. plasma for 2 to 3 weeks after treatment.1 The rebound in 3. Renard C, et al. Pharmacokinetics of dig,'><i<1-sp,eei1ie Fab: effects of severe facial and pulmonary oedema after treatment with decreased renal function and age. 1997; 44: 135-8. dicobalt edetate.1 It has been suggested that when dicobalt free-digoxin concentrations that has been reported after edetate is used, facilities for intubation and resuscitation treatment with digoxin-specific antibody fragments (see P (Jrations should be immediately available. Poisoning, below), occurred much later in patients with r.�p renal impairment than in those with normal renal func­ Proprietary Preparations (details are given in Volume B) 1. Dodds C, McKnight C. Cyanide toxicity after immersion and the hazards tion.
    [Show full text]
  • A Pilot Study in Detoxification of Heavy Metals
    The Role of Heavy Metal Detoxification in Heart Disease and Cancers : A Pilot Study in Detoxification of Heavy Metals Daniel Dugi, M.D. Sir Arnold Takemoto Presented at the WESCON Biomedicine and Bioengineering Conference Anaheim Convention Center The Future of Medicine Afternoon Session September 24, 2002 Anaheim, California USA 1 ABSTRACT Heavy metal detoxification has been shown to decrease cancer mortality by 90% in a 18-year controlled clinical study by Blumer and Cranton. Frustachi et. al. has shown a very strong correlation between cardiomyopathy (heart disease) and heavy metals accumulation in the coronary arteries and heart muscle. The role of heavy metal detoxification in the prevention and/or treatment of cancers and heart disease is paramount for optimum healing or prevention. Heavy metal accumulation can cause suppression of the immune system, bind receptor sites, inhibit proper enzyme systems, and lead to undesirable free-radical and oxidative functions. A pilot study utilizing a unique oral detoxifying concentrate, DeTox Max, containing true disodium EDTA, microencapsulated in essential phospholipids microspheres was utilized as a provocation, detoxifying agent for a 16 patient pilot study. Significant quantities of heavy metals were excreted in a 48-hour collection versus each patient’s baseline 24 hour collection. The pilot study results confirmed substantial excretion of heavy metals. A surprising outcome of the study was the remarkable clinical healing and significant increase in brain acuity in patients that occurred within 2 weeks after only one vial was utilized, compared to previous pre - provocation. 2 Detox MAX Clinical Study Proposal ¾ To assess the heavy metal detoxifying ability of Detox MAX, an oral detoxification agent containing 22 grams of essential phospholipids (EPL’s); micro- encapsulating 1 gram of sodium endetate.
    [Show full text]
  • Post-Injury Calcium Chelation Rescues Skeletal Muscle Regeneration in Mice Matthew .D Magda University of Connecticut - Storrs, [email protected]
    University of Connecticut OpenCommons@UConn Honors Scholar Theses Honors Scholar Program Summer 8-1-2013 Post-Injury Calcium Chelation Rescues Skeletal Muscle Regeneration in Mice Matthew .D Magda University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses Part of the Cell Biology Commons, and the Molecular Biology Commons Recommended Citation Magda, Matthew D., "Post-Injury Calcium Chelation Rescues Skeletal Muscle Regeneration in Mice" (2013). Honors Scholar Theses. 321. https://opencommons.uconn.edu/srhonors_theses/321 1 Post-Injury Calcium Chelation Rescues Skeletal Muscle Regeneration in Mice Honors Thesis Matthew Magda Research Advisor: Dr. Morgan Carlson Honors Advisor: Dr. Kenneth Noll August 2013 2 Abstract: Antibiotics, surgery and organ transplants have pushed average lifespans towards the upper limits of the human body. Drastically reduced morbidity from infection, toxins and traumatic injury have allowed ever greater portions of the populace can reach eighty or ninety years old before dying of old age. Despite the increased role of aging as a source of morbidity, many aspects of aging are poorly characterized. Sarcopenia, progressive muscle loss, and loss of adult myogenic potential, the ability to produce new muscle tissue from adult stem cell sources, are key causes of decreased mobility and strength in aged individuals. If more youthful muscle quality could be restored in old patients they would experience greatly improved quality of life and perhaps even longer lifespans. Satellite cell populations are known to decline sharply by 6-7th decade of life but traditional treatments for sarcopenia, namely exercise intervention, have been shown to exacerbate the degeneration in aged such patients.
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Chelation of Actinides
    UC Berkeley UC Berkeley Previously Published Works Title Chelation of Actinides Permalink https://escholarship.org/uc/item/4b57t174 Author Abergel, RJ Publication Date 2017 DOI 10.1039/9781782623892-00183 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Chapter 6 Chelation of Actinides rebecca J. abergela aChemical Sciences Division, lawrence berkeley National laboratory, One Cyclotron road, berkeley, Ca 94720, USa *e-mail: [email protected] 6.1 The Medical and Public Health Relevance of Actinide Chelation the use of actinides in the civilian industry and defense sectors over the past 60 years has resulted in persistent environmental and health issues, since a large inventory of radionuclides, including actinides such as thorium (th), uranium (U), neptunium (Np), plutonium (pu), americium (am) and curium 1 Downloaded by Lawrence Berkeley National Laboratory on 22/06/2018 20:28:11. (Cm), are generated and released during these activities. Controlled process- Published on 18 October 2016 http://pubs.rsc.org | doi:10.1039/9781782623892-00183 ing and disposal of wastes from the nuclear fuel cycle are the main source of actinide dissemination. however, significant quantities of these radionu- clides have also been dispersed as a consequence of nuclear weapons testing, nuclear power plant accidents, and compromised storage of nuclear materi- als.1 In addition, events of the last fifteen years have heightened public con- cern that actinides may be released as the result of the potential terrorist use of radiological dispersal devices or after a natural disaster affecting nuclear power plants or nuclear material storage sites.2,3 all isotopes of the 15 ele- ments of the actinide series (atomic numbers 89 through 103, Figure 6.1) are radioactive and have the potential to be harmful; the heaviest members, however, are too unstable to be isolated in quantities larger than a few atoms at a time,4 and those elements cited above (U, Np, pu, am, Cm) are the most RSC Metallobiology Series No.
    [Show full text]
  • Recognizing and Managing Lead and Mercury Poisonings
    URGENT CARE Special Section Recognizing and Managing Lead and Mercury Poisonings After iron, which was covered in EM’s May issue, lead and mercury are the two metals most likely to be implicated in heavy metal toxicity syndromes. The authors review the diagnostic considerations and update guidelines for detoxification. hat constitutes a heavy metal? It de- W pends on who you ask. In industrial and environ- mental studies, heavy metals are generally defined as those elements that have high atomic weights—elements with a spe- cific gravity of 5 or higher. A strict chemistry definition classifies ev- Urgent Care Section Urgent Care erything between copper and bis- muth on the periodic table as a heavy metal. Medical usage of the term, however, is much more lib- Inc Researchers, Associates/Photo © 2009 Biphoto eral, encompassing lighter metals Chronic Effects of Lead Poisoning. Dark or bluish discoloration and metalloids that are excluded of the gum-tooth line, known as a “lead line,” may be noted on exam and is the result of a chemical reaction between lead and dental plaque. by other definitions. The list of medically recognized toxic met- als and metalloids includes (but is not limited to) aluminum, arse- poisonings can often result in sig- nic, barium, bismuth, cadmium, nificant morbidity and mortality if cobalt, copper, chromium, gold, unrecognized and inappropriately lead, manganese, mercury, sele- treated. The physician also needs Christian Balmadrid, MD nium, silver, thallium, and zinc.1 to be prepared for the postdiag- Staff Physician Heavy metal or metalloid tox- nostic responsibility of identifying Durham Emergency Physicians Durham Regional Hospital icity is relatively uncommon in possible exposures to the same Durham, North Carolina urgent care centers, but for that toxin within the patient’s family, very reason it is important to workplace, or community that Michael J.
    [Show full text]